Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma

Autor:	Yoshinobu Aisa, Masao Hagihara, Rika Sakai, Yotaro Tamai, Naohi Sahara, Eri Tanaka, Koji Miyazaki, Atsushi Wake, Ryuji Ishii, Shigehisa Tamaki, Morihiro Inoue, Kenji Tajika, Takeshi Kobayashi, Masaaki Higashihara, Shin Fujisawa, Tomonori Nakazato, Seiji Irie, Jian Hua
Rok vydání:	2021
Předmět:	Male medicine.medical_specialty Cyclophosphamide Frail Elderly Kaplan-Meier Estimate Newly diagnosed Dexamethasone Bortezomib Japan Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Prospective Studies Precision Medicine Multiple myeloma Aged Aged 80 and over Hematology business.industry Peripheral Nervous System Diseases General Medicine medicine.disease Hematologic Diseases Progression-Free Survival Thalidomide Clinical trial Treatment Outcome Female Multiple Myeloma business Hyponatremia medicine.drug
Zdroj:	Annals of Hematology. 100:2745-2754
ISSN:	1432-0584 0939-5555
Popis:	The Vulnerable Elders Survey-13 (VES-13) is a well-studied simplified frailty screening tool for elderly patients in the oncology setting. We conducted a prospective clinical trial to evaluate the efficacy and safety of dose-adjusted treatment based on the VES-13 in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). In the Fit group (VES-13
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b1e057ac056fc388c66695117546266 https://doi.org/10.1007/s00277-021-04592-y Zobrazit plný text záznamu Full text from SpringerLink